<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>ARTISS- fibrinogen human thrombin human 
			 </strong><br>Baxter Healthcare Corporation<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use ARTISS safely and
        effectively. See full prescribing information for ARTISS<br><br>ARTISS [Fibrin Sealant
        (Human)]<br>For Topical Use Only<br>Frozen solution and lyophilized powder for solution
        for topical application<br>includes DUPLOJECT<br>Initial U.S. Approval: 2008</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div>
<p class="Highlighta">Indications and Usage (<a href="#i4i_indications_duplicate_id_9058f319-a378-4997-b174-d92b054f6b6c">1.2</a>) 08/2011 </p>
<p class="Highlighta">Dosage and
                                    Administration (<a href="#i4i_section_id_bb65e1de-0810-44be-997e-054ff07ecbdb">2.3</a>) 08/2011 </p>
<p class="Highlighta">Adverse
                                    Reactions (<a href="#i4i_section_id_daed8dbc-1210-4b01-83df-891c036d1daa">6.1</a>) 08/2011 </p>
</div>
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><ul>
<li>ARTISS is indicated to adhere autologous skin grafts to
                                        surgically prepared <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span> beds resulting from <span class="product-label-link" type="condition" conceptid="4022094" conceptname="Thermal burn">burns</span> in adult
                                        and pediatric populations greater than or equal to 1 year of
                                        age (<a href="#i4i_indications_id_8fa09d2f-e1b5-43c9-bf90-b4574f96a814">1</a>)</li>
<li>ARTISS is indicated to adhere tissue flaps during facial
                                        rhytidectomy surgery (face-lift) (<a href="#i4i_section_id_497952d3-5be9-4e89-952f-790ea859137e">1.2</a>)</li>
<li>ARTISS is not indicated as an adjunct to hemostasis
                                            (<a href="#i4i_indications_id_8fa09d2f-e1b5-43c9-bf90-b4574f96a814">1</a>)</li>
</ul></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<p class="Highlighta"><span class="Bold">For Topical Use Only. Do Not Inject
                                            (<a href="#i4i_dosage_admin_id_7402bd9f-c3ae-4f3f-ac6d-989afd973045">2</a>). Apply on surface of prepared <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span> beds
                                        only (<a href="#i4i_section_id_bb65e1de-0810-44be-997e-054ff07ecbdb">2.3</a>)</span> </p>
<p class="Highlighta">ARTISS Kit (Freeze-Dried) requires
                                    reconstitution prior to use (<a href="#i4i_section_id_497952d3-5be9-4e89-952f-790ea859137e">2.1</a>) </p>
<p class="Highlighta">ARTISS Pre-filled
                                    Syringe (Frozen) requires thawing prior to use (<a href="#i4i_section_id_7702f974-1084-4dc4-b44c-04201aff827d">2.2</a>) </p>
<p class="Highlighta">Apply as a thin layer
                                    using the Easyspray and Spray Set (<a href="#i4i_section_id_bb65e1de-0810-44be-997e-054ff07ecbdb">2.3</a>, <a href="#i4i_section_id_321c4972-8462-4049-a168-8e45dfe39750">5.2</a>) </p>
<p class="Highlighta">Dosage: 2 mL will
                                    cover approximately 100 cm<span class="Sup">2</span> surface area (<a href="#i4i_dosage_admin_id_7402bd9f-c3ae-4f3f-ac6d-989afd973045">2</a>)  </p>
<p class="Highlighta">Vials and pre-filled
                                    syringes are for single use only. Discard unused contents
                                        (<a href="#i4i_section_id_bb65e1de-0810-44be-997e-054ff07ecbdb">2.3</a>) </p>
</div>
<div></div>
<div><div></div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">ARTISS is available as a two-component fibrin sealant,
                                    including Sealer Protein (Human) and Thrombin (Human), in two
                                    dosage forms, 2 mL, 4 mL and 10 mL Freeze-Dried Kit and 2 mL, 4
                                    mL and 10 mL Frozen Solution in Pre-filled Syringe (<a href="#i4i_dosage_form_strength_id_22ad3d16-2cb7-4985-a242-c8fe3407d5b0">3</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul>
<li>Do not inject directly into the circulatory system
                                            (<a href="#i4i_section_id_1a2cdec6-e569-4e95-9995-a168984da125">4.1</a>)</li>
<li>Do not use in individuals with a known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to
                                        aprotinin (<a href="#i4i_section_id_77bbbbac-f1e6-4271-bccb-51dde383bd7c">4.2</a>, <a href="#i4i_section_id_f1d4513e-d30c-4660-95e6-a28cec857c7d">5.1</a>)</li>
</ul></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul>
<li><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> or allergic/<span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span> may
                                        occur with the use of ARTISS (<a href="#i4i_section_id_f1d4513e-d30c-4660-95e6-a28cec857c7d">5.1</a>)</li>
<li>Air or gas <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">embolism</span> has occurred with the use of spray
                                        devices employing pressure regulator to administer fibrin
                                        sealants. This event appears to be related to the use of the
                                        spray device at higher than recommended pressures and in
                                        close proximity to the surface of the tissue (<a href="#i4i_section_id_321c4972-8462-4049-a168-8e45dfe39750">5.2</a>)</li>
<li>Exposure to solutions containing alcohol, iodine or heavy
                                        metals may cause ARTISS to be denatured (<a href="#i4i_section_id_321c4972-8462-4049-a168-8e45dfe39750">5.3</a>)</li>
<li>Apply only as thin layer (<a href="#i4i_section_id_bb65e1de-0810-44be-997e-054ff07ecbdb">2.3,</a><a href="#i4i_warnings_precautions_duplicate_id_bfbf1783-a3df-486a-afb5-a532e083082a">5.3</a>)</li>
<li>ARTISS is made from human plasma and may contain
                                        infectious agents, e.g., viruses and theoretically,
                                        Creutzfeldt-Jacob disease (CJD) agent. (<a href="#i4i_section_id_8535bc13-2899-4367-9f7b-4e292f8b891d">5.4</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">Adverse reactions reported during clinical trials in
                                    greater than 1% for subjects
                                        were: </p>
<p class="Highlighta"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4022094" conceptname="Thermal burn">Burns</span></span>: <span class="product-label-link" type="condition" conceptid="4308404" conceptname="Skin graft failure">skin graft failure</span>, <span class="product-label-link" type="condition" conceptid="4147001" conceptname="Hematoma">hematoma</span> and <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>
                                        (<a href="#i4i_section_id_daed8dbc-1210-4b01-83df-891c036d1daa">6.1</a>) </p>
<p class="Highlighta"><span class="Bold">Facial Rhytidectomy</span>:
                                    <span class="product-label-link" type="condition" conceptid="4147001" conceptname="Hematoma">hematoma</span>/<span class="product-label-link" type="condition" conceptid="4209136" conceptname="Seroma">seroma</span> (<a href="#i4i_section_id_daed8dbc-1210-4b01-83df-891c036d1daa">6.1</a>) </p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS,
                                        contact Baxter Healthcare Corporation at 1-866-888-2472 or
                                        FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</span> </p>
</div>
<div></div>
<div></div>
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><p class="Highlighta">Pregnancy: No human or animal data. Use ARTISS only if
                                    clearly needed (<a href="#i4i_pregnancy_id_551d72ae-0a2c-4a33-860f-8a30eb448085">8.1</a>) </p></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div><div></div></div>
<div><div></div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 8/2011</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h2><a href="#section-1.1" class="toc">1.1 <span class="product-label-link" type="condition" conceptid="4022094" conceptname="Thermal burn">Burns</span></a></h2>
<h2><a href="#section-1.2" class="toc"><span class="XmChange">1.2 Facial
                                Rhytidectomy</span></a></h2>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Preparation of ARTISS Kit (Freeze-Dried)</a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Preparation of ARTISS Pre-filled Syringe (Frozen)</a></h2>
<h2><a href="#section-2.3" class="toc">2.3 Method of Application</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h2><a href="#section-4.1" class="toc">4.1 Intravascular Application</a></h2>
<h2><a href="#section-4.2" class="toc">4.2 Aprotinin <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span></a></h2>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span>/Allergic/<span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylactic Reactions</span></a></h2>
<h2><a href="#section-5.2" class="toc">5.2 Air or Gas <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">Embolism</span></a></h2>
<h2><a href="#section-5.3" class="toc">5.3 Application Precautions</a></h2>
<h2><a href="#section-5.4" class="toc">5.4 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span> Risk from Human Plasma</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trials Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Post-Marketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.2 Pharmacodynamics</a></h2>
<h2><a href="#section-11.3" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h2><a href="#section-13.1" class="toc">14.1 <span class="product-label-link" type="condition" conceptid="4022094" conceptname="Thermal burn">Burns</span> (grafts)</a></h2>
<h1><a href="#section-14" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-15" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_8fa09d2f-e1b5-43c9-bf90-b4574f96a814"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_duplicate_id_72af50dc-0a0c-43f8-8c15-66ddbaf9ae4c"></a><a name="section-1.1"></a><p></p>
<h2>1.1 <span class="product-label-link" type="condition" conceptid="4022094" conceptname="Thermal burn">Burns</span></h2>
<p class="First">ARTISS is indicated to adhere autologous skin grafts to
                                    surgically prepared <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span> beds resulting from <span class="product-label-link" type="condition" conceptid="4022094" conceptname="Thermal burn">burns</span> in adult and
                                    pediatric populations greater than or equal to 1 year of
                                    age.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_duplicate_id_9058f319-a378-4997-b174-d92b054f6b6c"></a><a name="section-1.2"></a><p></p>
<h2 style="border-left:1px solid;"><span class="XmChange">1.2 Facial
                                Rhytidectomy</span></h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">ARTISS is indicated to
                                        adhere tissue flaps during facial rhytidectomy surgery
                                        (face-lift).</span></p>
<p> </p>
<p>ARTISS
                                    is not indicated as an adjunct to hemostasis.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_7402bd9f-c3ae-4f3f-ac6d-989afd973045"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<p class="First"><span class="Bold">FOR TOPICAL USE ONLY – DO NOT
                                INJECT.</span></p>
<p>The amount of ARTISS to be applied must be
                            individualized by the treating physician based on the size of the
                            surface to be covered. The approximate surface areas covered by each
                            package size of ARTISS are:</p>
<a name="id_8caa3e08-6f57-4c20-8521-aa57c3e03f25"></a><table width="600.000">
<caption><span>Table 1.</span></caption>
<col align="center" width="50.0%">
<col align="center" width="50.0%">
<thead><tr class="First Last">
<td class="Lrule Rrule Toprule" align="center" valign="top"><span class="Bold">Approximate area requiring
                                            skin graft fixation</span></td>
<td class="Rrule" align="center" valign="top"><span class="Bold">Required package size of
                                            ARTISS</span></td>
</tr></thead>
<tbody>
<tr class="First">
<td class="Lrule Rrule Toprule" align="center" valign="top">100 cm<span class="Sup">2</span>
</td>
<td class="Rrule" align="center" valign="top">2 mL</td>
</tr>
<tr>
<td class="Lrule Rrule" align="center" valign="top">200
                                            cm<span class="Sup">2</span>
</td>
<td class="Rrule" align="center" valign="top">4 mL</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="center" valign="top">500 cm<span class="Sup">2</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">10
                                        mL</td>
</tr>
</tbody>
</table>
<p>It is recommended that every time a patient receives a
                            dose of ARTISS the name and lot number (batch number) of the product are
                            documented in order to maintain link between the patient and product
                            batch.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_497952d3-5be9-4e89-952f-790ea859137e"></a><a name="section-2.1"></a><p></p>
<h2>2.1 Preparation of ARTISS Kit (Freeze-Dried)</h2>
<p class="First"><span class="Bold">During preparation of ARTISS
                                        Kit:</span></p>
<p><span class="Bold">DO NOT EXPOSE TO
                                        TEMPERATURES ABOVE
                                        37°C</span></p>
<p><span class="Bold">DO NOT REFRIGERATE OR FREEZE AFTER
                                        RECONSTITUTION </span></p>
<p><span class="Bold">Do not use iodine or heavy metal containing
                                        preparations such as betadine for disinfection of vial
                                        stoppers. Allow alcohol-based disinfectants to evaporate
                                        before puncturing stopper.</span></p>
<p>After reconstitution, the product must be
                                    used within 4 hours.</p>
<p>Use separate syringes
                                    for reconstituting Sealer Protein and Thrombin solutions and for
                                    application to prevent premature
                                    clotting.</p>
<p>ARTISS Kit contains the
                                    following substances in four separate vials: </p>
<dl>
<dt> </dt>
<dd> -Sealer Protein Concentrate
                                        (Human)</dd>
<dt> </dt>
<dd> -<span class="product-label-link" type="condition" conceptid="4299457" conceptname="Fibrinolysis">Fibrinolysis</span> Inhibitor Solution
                                        (Synthetic)</dd>
<dt> </dt>
<dd> -Thrombin (Human)</dd>
<dt> </dt>
<dd> -Calcium Chloride Solution</dd>
</dl>
<p>Freeze-dried Sealer Protein Concentrate and
                                    Thrombin are reconstituted in <span class="product-label-link" type="condition" conceptid="4299457" conceptname="Fibrinolysis">Fibrinolysis</span> Inhibitor Solution
                                    and Calcium Chloride Solution, respectively. The Sealer Protein
                                    Solution and Thrombin Solution are then combined using the
                                    DUPLOJECT Preparation and Application System, or an equivalent
                                    delivery device cleared by FDA for use with ARTISS to form the
                                    Fibrin Sealant.</p>
<p><span class="Bold">Prewarming ARTISS Kit with FIBRINOTHERM</span></p>
<p>If a FIBRINOTHERM device is not available,
                                    contact Baxter (1-800-423-2090) for assistance. See FIBRINOTHERM
                                    manual for complete operating instructions.</p>
<ol>
<li>Plug the FIBRINOTHERM Heating and Stirring Device into an
                                        electrical socket and activate the warmer (amber switch).
                                        Ensure that the stirring mechanism of the FIBRINOTHERM
                                        device is initially switched off (green switch).</li>
<li>Place all four vials from the ARTISS Kit into the
                                        prewarmed wells of the FIBRINOTHERM, using the appropriately
                                        sized adapter rings, and allow the vials to warm for up to 5
                                        minutes (room temperature product may take less
                                        time).</li>
</ol>
<p><span class="Bold">Preparation of Sealer Protein Solution
                                        with FIBRINOTHERM</span></p>
<ol>
<li>Remove the flip-off caps from the vial containing the
                                        Sealer Protein Concentrate and the vial containing the
                                        <span class="product-label-link" type="condition" conceptid="4299457" conceptname="Fibrinolysis">Fibrinolysis</span> Inhibitor Solution, disinfect the rubber
                                        stoppers of both vials with a germicidal solution and allow
                                        to dry.</li>
<li>Transfer the <span class="product-label-link" type="condition" conceptid="4299457" conceptname="Fibrinolysis">Fibrinolysis</span> Inhibitor Solution into the vial
                                        containing the freeze-dried Sealer Protein Concentrate using
                                        the sterile reconstitution components provided with the
                                        DUPLOJECT Preparation and Application System, or an
                                        equivalent device cleared by FDA for use with ARTISS (see
                                        directions provided with the device system for specific
                                        reconstitution instructions). Gently swirl the vial to
                                        ensure that the freeze-dried material is completely
                                        soaked.</li>
<li>Place the vial into the largest opening of the
                                        FIBRINOTHERM device with the appropriate adaptor. Switch on
                                        the stirrer (green switch) and allow the vial contents to
                                        stir until all Sealer Protein Concentrate is
                                        dissolved.</li>
<li>Reconstitution of the freeze-dried Sealer Protein
                                        Concentrate is complete as soon as no undissolved particles
                                        are visible. Otherwise, return the vial to the FIBRINOTHERM
                                        device and agitate for a few more minutes until the solution
                                        appears homogeneous.</li>
</ol>
<p><span class="Bold">Notes:</span></p>
<ul>
<li>Do not use the Sealer Protein Concentrate until it has
                                        fully dissolved. If the Sealer Protein Concentrate has not
                                        dissolved within 20 minutes using the FIBRINOTHERM device,
                                        discard the vial and prepare a fresh kit. Excessive stirring
                                        (20 minutes or more) may compromise product quality.</li>
<li>If not used promptly, keep the Sealer Protein Solution at
                                        37°C without stirring. To ensure homogeneity, switch on the
                                        stirrer of the FIBRINOTHERM device shortly before drawing up
                                        the solution.</li>
</ul>
<p><span class="Bold">Preparation of Thrombin Solution with
                                        FIBRINOTHERM</span></p>
<ol>
<li>Remove the flip-off caps from the vial containing Thrombin
                                        and the vial containing Calcium Chloride Solution, disinfect
                                        the rubber stoppers of both vials with a germicidal solution
                                        and allow to dry.</li>
<li>Transfer the contents of the vial with Calcium Chloride
                                        Solution into the vial containing the freeze-dried Thrombin
                                        using the sterile reconstitution components provided with
                                        the DUPLOJECT Preparation and Application System, or an
                                        equivalent device cleared by FDA for use with ARTISS (see
                                        directions provided with the device system for specific
                                        reconstitution instructions).</li>
<li>Swirl briefly.</li>
<li>Place the vial into the adapted opening of the
                                        FIBRINOTHERM device.</li>
<li>Reconstitution of Thrombin is complete when all of the
                                        Thrombin concentrate is dissolved.</li>
<li>Keep the Thrombin Solution at 37°C until used.</li>
</ol>
<p><span class="Bold">Transferring to the
                                        Sterile Field</span></p>
<p>For transfer of the Sealer Protein Solution
                                    and the Thrombin Solution to the sterile field, the scrub nurse
                                    should withdraw the solutions while the circulating nurse holds
                                    the non-sterile vials. The solutions should be withdrawn slowly
                                    by firm constant <span class="product-label-link" type="condition" conceptid="4239038" conceptname="Pulmonary aspiration">aspiration</span> to reduce the risk of large air
                                    bubbles.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_7702f974-1084-4dc4-b44c-04201aff827d"></a><a name="section-2.2"></a><p></p>
<h2>2.2 Preparation of ARTISS Pre-filled Syringe (Frozen)</h2>
<p class="First"><span class="Bold">During preparation of ARTISS
                                        (frozen):</span></p>
<p><span class="Bold">DO NOT EXPOSE TO
                                        TEMPERATURES ABOVE 37°C<br>DO NOT MICROWAVE<br>DO NOT
                                        REFRIGERATE OR RE-FREEZE AFTER THAWING</span></p>
<p>Do not use ARTISS (frozen) unless it is
                                    completely thawed and warmed (liquid consistency).
                                    </p>
<p>Do not remove the protective syringe cap
                                    until thawing is complete and the application tip is ready to be
                                    attached. </p>
<p>ARTISS (frozen) can be prepared
                                    (thawed) using one of two
                                        options:</p>
<p><span class="Underline"><span class="Bold">Room
                                            Temperature Thawing</span></span></p>
<p>Approximate thawing times when using this
                                    method are:</p>
<a name="id_4527a3fc-f305-479a-80be-8335ffc88ab6"></a><table width="600.000">
<col align="center" width="50.0%">
<col align="center" width="50.0%">
<thead><tr class="First Last">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><span class="Bold">Pack
                                                  Size</span></td>
<td class="Botrule Rrule" align="center" valign="bottom"><span class="Bold">Room
                                                  Temperature<br>(In Pouches)</span></td>
</tr></thead>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">2 mL</td>
<td class="Botrule Rrule" align="center" valign="bottom">60 minutes</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="bottom">4 mL</td>
<td class="Botrule Rrule" align="center" valign="bottom">110 minutes</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="center" valign="bottom">10 mL</td>
<td class="Botrule Rrule" align="center" valign="bottom">160 minutes</td>
</tr>
</tbody>
</table>
<p style="border-left:1px solid;">Unopened pouches, thawed at room temperature, may
                                    be stored for up to 14 days at 15-25°C<span class="XmChange">.</span></p>
<p>Prior
                                    to use, the product should be warmed to
                                    33-37°C:</p>
<a name="id_8760dc66-2b3a-4c73-84a1-b134aaa44cce"></a><table width="600.000">
<col align="center" width="50.0%">
<col align="center" width="50.0%">
<thead><tr class="First Last">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><span class="Bold">Pack
                                                  Size</span></td>
<td class="Botrule Rrule" align="center" valign="bottom"><span class="Bold">33°C to
                                                  37°C Incubator<br>(In Pouches)</span></td>
</tr></thead>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">2 mL</td>
<td class="Botrule Rrule" align="center" valign="bottom">15 minutes</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="bottom">4 mL</td>
<td class="Botrule Rrule" align="center" valign="bottom">25 minutes</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="center" valign="bottom">10 mL</td>
<td class="Botrule Rrule" align="center" valign="bottom">35 minutes</td>
</tr>
</tbody>
</table>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_a03b15ec-cf95-4e9d-be20-69b7e3d1aefa"></a><a name="section-2.2.1"></a><p></p>
<p class="First"><span class="Underline"><span class="Bold">Quick Thawing </span></span></p>
<p><span class="Underline">Thawing on the sterile field using a water
                                                bath</span></p>
<p>33°C to 37°C sterile water bath -
                                            transfer the inner pouch to the sterile field, remove
                                            pre-filled syringe from inner pouch and place directly
                                            into sterile water bath. Ensure the contents of the
                                            pre-filled syringe are completely immersed under the
                                            water.</p>
<p>Approximate thawing times
                                            when using this method are: </p>
<a name="id_2f530a98-f0af-4c47-9b3b-1745cf909c3f"></a><table width="600.000">
<col align="center" width="50.0%">
<col align="center" width="50.0%">
<thead><tr class="First Last">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><span class="Bold">Pack
                                                  Size</span></td>
<td class="Botrule Rrule" align="center" valign="bottom"><span class="Bold">33°C to
                                                  37°C Sterile Water Bath<br>(Pouches
                                                  Removed)</span></td>
</tr></thead>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">2 mL</td>
<td class="Botrule Rrule" align="center" valign="bottom">5 minutes</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="bottom">4 mL</td>
<td class="Botrule Rrule" align="center" valign="bottom">5 minutes</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="center" valign="bottom">10 mL</td>
<td class="Botrule Rrule" align="center" valign="bottom">12 minutes</td>
</tr>
</tbody>
</table>
<p><span class="Underline">Thawing
                                                off the sterile field using a water bath</span></p>
<p>33°C to 37°C non-sterile water bath
                                            in two pouches - maintain the pre-filled syringe in both
                                            pouches and place into a water bath off the sterile
                                            field for appropriate time. Ensure the pouches remain
                                            submerged throughout thawing. Remove from the water bath
                                            after thawing, dry external pouch and transfer inner
                                            pouch with pre-filled syringe onto the sterile
                                            field.</p>
<p>Approximate thawing times
                                            when using this method are:</p>
<a name="id_50c51fc5-d9c3-4a21-a2e5-e01155d2a59d"></a><table width="600.000">
<col align="center" width="50.0%">
<col align="center" width="50.0%">
<thead><tr class="First Last">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><span class="Bold">Pack
                                                  Size</span></td>
<td class="Botrule Rrule" align="center" valign="bottom"><span class="Bold">33°C to
                                                  37°C Non-Sterile Water Bath<br>(In
                                                  Pouches)</span></td>
</tr></thead>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">2 mL</td>
<td class="Botrule Rrule" align="center" valign="bottom">30 minutes</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="bottom">4 mL</td>
<td class="Botrule Rrule" align="center" valign="bottom">40 minutes</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="center" valign="bottom">10 mL</td>
<td class="Botrule Rrule" align="center" valign="bottom">80 minutes</td>
</tr>
</tbody>
</table>
<p><span class="Underline">Thawing
                                                off the sterile field using an incubator</span></p>
<p>33°C to 37°C incubator in pouches –
                                            maintain the pre-filled syringe in both pouches and
                                            place into an incubator for appropriate time. Remove
                                            from incubator after thawing and transfer inner pouch
                                            with pre-filled syringe onto the sterile
                                            field.</p>
<p>Approximate thawing times
                                            when using this method are: </p>
<a name="id_10ef5fb5-c224-4d0c-b5e1-aa743a05f0c8"></a><table width="600.000">
<col align="center" width="50.0%">
<col align="center" width="50.0%">
<thead><tr class="First Last">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><span class="Bold">Pack
                                                  Size</span></td>
<td class="Botrule Rrule" align="center" valign="bottom"><span class="Bold">33°C to
                                                  37°C Incubator<br>(In Pouches)</span></td>
</tr></thead>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">2 mL</td>
<td class="Botrule Rrule" align="center" valign="bottom">40 minutes</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="bottom">4 mL</td>
<td class="Botrule Rrule" align="center" valign="bottom">85 minutes</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="center" valign="bottom">10 mL</td>
<td class="Botrule Rrule" align="center" valign="bottom">105 minutes</td>
</tr>
</tbody>
</table>
<p>Maintain the product at 33-37°C until
                                            use. If product is removed from original pouch or warmed
                                            to 33-37°C it must be used within 12
                                        hours.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_bb65e1de-0810-44be-997e-054ff07ecbdb"></a><a name="section-2.3"></a><p></p>
<h2>2.3 Method of Application</h2>
<p class="First">Apply ARTISS using the Easyspray and Spray Set, or an
                                    equivalent device cleared by FDA for application of ARTISS. See
                                    additional instructions for use provided with the spray
                                    set.</p>
<p>The <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span> surface should be as dry as
                                    possible before application.</p>
<p style="border-left:1px solid;"><span class="XmChange">Ensure that parts of the body outside
                                        the desired application area are sufficiently covered to
                                        prevent tissue adherence at undesired
                                    site.</span></p>
<p>Apply ARTISS as a thin
                                    layer to avoid the formation of excess granulation tissue and to
                                    ensure gradual absorption of the polymerized fibrin sealant.
                                    </p>
<p>The aerosolized sealant should be applied
                                    to the <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span> in a painting motion from side to side to achieve a
                                    single thin application. The <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span> bed will glisten in the area
                                    to which fibrin sealant has been applied.
                                    </p>
<p>Any areas not covered by fibrin sealant
                                    will be clearly visible. </p>
<p>The skin flap or
                                    graft should be attached to the <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span> bed immediately after
                                    ARTISS has been sprayed. The surgeon has up to 60 seconds to
                                    manipulate and position the flap or graft prior to
                                    polymerization. The initial amount of the product to be applied
                                    should be sufficient to cover the intended application area.
                                    </p>
<p>The application can be repeated, if
                                    necessary, to any small areas that may not have been previously
                                    treated. To prevent adherence, wet gloves with normal saline
                                    before product contact.</p>
<p>After the flap or
                                    graft has been positioned, hold in the desired position by
                                    gentle compression for at least 3 minutes to ensure ARTISS sets
                                    properly and adheres firmly to the surrounding tissue. The
                                    solidified fibrin sealant reaches its final strength in
                                    approximately 2 hours after
                                    application.</p>
<p>The cannulas included with
                                    the DUPLOJECT Preparation and Application System or DUO Set may
                                    be used for small <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wounds</span> or for edges of a skin graft that did
                                    not adhere to the <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span> bed  <span class="Italics">(<a href="#i4i_section_id_321c4972-8462-4049-a168-8e45dfe39750">see WARNINGS/PRECAUTIONS Application Precautions
                                            (5.3</a>)). </span>Immediately before
                                    application, expel and discard the first several drops from the
                                    application cannula to ensure adequate mixing of the Sealer
                                    Protein and Thrombin solutions in cases where very small volumes
                                    (1-2 drops) are administered.</p>
<dl>
<dt> </dt>
<dd>Freeze-Dried: Refer to instructions
                                        for use provided with the DUPLOJECT Preparation and
                                        Application System.</dd>
<dt> </dt>
<dd>Frozen: DUO Set Instructions (see
                                        Figure 1 below): </dd>
</dl>
<ol>
<li>Insert plunger into syringe barrel.</li>
<li>Firmly connect the two syringe nozzles to the joining
                                        piece and secure it by fastening the tether strap to the
                                        syringe.</li>
<li>Fit an application cannula to the joining
                                            piece.<p class="First">If application of ARTISS is
                                            interrupted, replace the cannula immediately before
                                            application is resumed.</p>
</li>
</ol>
<div class="Figure">
<img alt="DUO set indicating syringe barrel, 2 syringe nozzles with joining
                                piece and application cannula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=38a6412e-9557-45ad-a917-da15109657ec&amp;name=906c38fb-0400-4440-8cc8-de27b2836640-01.jpg"><p class="MultiMediaCaption">Figure 1
                                        DUO SET A</p>
</div>
<p>Vials and pre-filled syringes are for
                                    single use only. Discard unused contents. </p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="i4i_dosage_form_strength_id_22ad3d16-2cb7-4985-a242-c8fe3407d5b0"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">ARTISS is available as a two-component fibrin sealant,
                            including Sealer Protein (Human) and Thrombin (Human), in two dosage
                            forms 2 mL, 4 mL and 10 mL Freeze-Dried Kit and 2 mL, 4 mL and 10 mL
                            Frozen Solution in Pre-filled Syringe. </p>
<p>The
                            reconstituted solution or pre-filled syringe
                            contains:</p>
<p>Sealer Protein
                            Solution</p>
<a name="id_44a1f543-d4c2-487f-a5b1-e6020cd92f3d"></a><table width="501.000">
<col align="left" width="5.2%">
<col align="left" width="34.9%">
<col align="left" width="59.9%">
<tbody class="Headless">
<tr class="First">
<td class="Toprule" align="left" valign="top"></td>
<td class="Toprule" align="left" valign="top">Total
                                        protein:</td>
<td align="left" valign="top">96 – 125 mg/mL</td>
</tr>
<tr>
<td align="left" valign="top"></td>
<td align="left" valign="top">Fibrinogen:</td>
<td align="left" valign="top">67 – 106 mg/mL</td>
</tr>
<tr>
<td align="left" valign="top"></td>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4299457" conceptname="Fibrinolysis">Fibrinolysis</span> Inhibitor
                                        (Synthetic):</td>
<td align="left" valign="top">2250 – 3750 KIU/mL</td>
</tr>
<tr class="Last">
<td class="Botrule" align="left" valign="top"></td>
<td class="Botrule" align="left" colspan="2" valign="top">Other ingredients include: human albumin, tri-sodium
                                        citrate, histidine, niacinamide, polysorbate 80 and water
                                        for injection (WFI).</td>
</tr>
</tbody>
</table>
<p>Thrombin Solution</p>
<a name="id_0618e9a7-4f0d-45df-8459-779527524a88"></a><table width="501.000">
<col align="left" width="5.2%">
<col align="left" width="34.9%">
<col align="left" width="59.9%">
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>The potency
                                            expressed in units is determined using a clotting assay
                                            against an internal reference standard for potency that
                                            has been calibrated against the World Health
                                            Organization (WHO) Second International Standard for
                                            Thrombin, 01/580. Therefore, a unit (U) is equivalent to
                                            an International Unit (IU).</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Toprule" align="left" valign="top"></td>
<td class="Toprule" align="left" valign="top">Thrombin
                                        (Human):</td>
<td align="left" valign="top">2.5 – 6.5 units/mL<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a>
</td>
</tr>
<tr>
<td align="left" valign="top"></td>
<td align="left" valign="top">Calcium Chloride:</td>
<td align="left" valign="top">36 – 44 µmol/mL</td>
</tr>
<tr class="Last">
<td class="Botrule" align="left" valign="top"></td>
<td class="Botrule" align="left" colspan="2" valign="top">Other ingredients include: human albumin, sodium chloride
                                        and water for injection (WFI).</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_0bc09769-a631-468f-a04c-c59bfd2c9aaf"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_1a2cdec6-e569-4e95-9995-a168984da125"></a><a name="section-4.1"></a><p></p>
<h2>4.1 Intravascular Application</h2>
<p class="First"><span class="Bold">Do not inject ARTISS directly
                                        into blood vessels. Intravascular application of ARTISS may
                                        result in life-threatening <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">thromboembolic events</span>.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_77bbbbac-f1e6-4271-bccb-51dde383bd7c"></a><a name="section-4.2"></a><p></p>
<h2>4.2 Aprotinin <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span></h2>
<p class="First">Do not use ARTISS in individuals with a known
                                    <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to aprotinin and/or <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to any of
                                    the active substances or excipients <span class="Italics">(see <a href="#i4i_section_id_f1d4513e-d30c-4660-95e6-a28cec857c7d">WARNINGS/PRECAUTIONS,
                                            <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span>/Allergic/<span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylactic Reactions</span>
                                            (5.1)</a> and <a href="#i4i_adverse_effects_id_17ac6258-3314-4087-9c9b-28637a29bca3">ADVERSE REACTIONS (6)</a>).</span></p>
</div>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="i4i_warnings_precautions_id_0d12bac6-0948-4863-9a6b-2940328f7965"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f1d4513e-d30c-4660-95e6-a28cec857c7d"></a><a name="section-5.1"></a><p></p>
<h2>5.1 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span>/Allergic/<span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylactic Reactions</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> or allergic/<span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span>
                                    may occur with the use of ARTISS. Cases have been reported in
                                    post marketing experience with fibrin sealant <span class="Italics">(see <a href="#i4i_section_id_74e83fe8-159a-4e36-8220-1a2777cda3c6">ADVERSE REACTIONS, Post-MarketingExperience
                                            (6.2)</a>)</span>. In specific cases, these
                                    reactions have progressed to become life-threatening. Such
                                    reactions may especially be seen if ARTISS is applied repeatedly
                                    over time or in the same setting, or if systemic aprotinin has
                                    been administered previously; however, these reactions may also
                                    occur in patients receiving ARTISS for the first time. Even if
                                    the first treatment was well tolerated, a subsequent
                                    administration of ARTISS or systemic aprotinin may not exclude
                                    the occurrence of an <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>. Symptoms associated with
                                    allergic <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span> include: flush, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>,
                                    <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="314171" conceptname="Low blood pressure reading">drop in blood pressure</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span> or
                                    <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, severe <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> and <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic shock</span>.
                                    </p>
<p>Aprotinin is included in ARTISS for its
                                    antifibrinolytic properties. Aprotinin, a monomeric polypeptide,
                                    is known to be associated with <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span>. Even in
                                    the case of strict local application of aprotinin, there is a
                                    risk of <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span> to aprotinin, particularly in the
                                    case of previous exposure <span class="Italics">(see
                                        CONTRAINDICATIONS, Aprotinin <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> (<a href="#i4i_section_id_77bbbbac-f1e6-4271-bccb-51dde383bd7c">4.2</a>)).</span></p>
<p>Discontinue administration of ARTISS in the
                                    event of anaphylactic/-oid or <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span>. Remove
                                    the already applied, polymerized product from the surgical
                                    field. Mild reactions can be managed with antihistamines. Severe
                                    reactions and reactions involving <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> require immediate
                                    resuscitative intervention.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_321c4972-8462-4049-a168-8e45dfe39750"></a><a name="section-5.2"></a><p></p>
<h2>5.2 Air or Gas <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">Embolism</span></h2>
<p class="First"> Air or gas <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">embolism</span> has occurred with the use of spray
                                    devices employing pressure regulator to administer fibrin
                                    sealants. This event appears to be related to the use of the
                                    spray device at higher than recommended pressures and in close
                                    proximity to the tissue surface. </p>
<p> When
                                    applying ARTISS using a spray device, be sure to use the
                                    pressure within the pressure range recommended by the spray
                                    device manufacturer. In the absence of a specific recommendation
                                    avoid using pressure above 20-25 psi. Do not spray closer than
                                    the distance recommended by the spray device manufacturer. In
                                    the absence of a specific recommendation avoid spraying closer
                                    than 10-15 cm from the surface of the tissue. When spraying
                                    ARTISS, changes in blood pressure, pulse, oxygen saturation and
                                    end tidal CO<span class="Sub">2</span> should be monitored because of the
                                    possibility of occurrence of air or gas <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">embolism</span>. When using the
                                    Easyspray device, or an equivalent spray device cleared by FDA,
                                    use the pressure within the pressure range recommended by the
                                    spray device manufacturer. Spray ARTISS only on to visible
                                    application sites. </p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="i4i_warnings_precautions_duplicate_id_bfbf1783-a3df-486a-afb5-a532e083082a"></a><a name="section-5.3"></a><p></p>
<h2>5.3 Application Precautions</h2>
<p class="First">The sealer protein and thrombin solutions can be
                                    denatured by alcohol, iodine or heavy metal ions (e.g.
                                    antiseptic solutions). If any of these substances have been used
                                    to clean the <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span> area, the area must be thoroughly rinsed
                                    before application of ARTISS and made as dry as
                                    possible.</p>
<p>Apply ARTISS as a thin layer.
                                    Excessive clot thickness may delay the natural <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span> healing
                                    process.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_8535bc13-2899-4367-9f7b-4e292f8b891d"></a><a name="section-5.4"></a><p></p>
<h2>5.4 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span> Risk from Human Plasma</h2>
<p class="First">ARTISS is made from human plasma. Products made from
                                    human plasma may contain infectious agents, such as viruses,
                                    that can cause disease. The risk that such products will
                                    transmit an infectious agent has been reduced by screening
                                    plasma donors for prior exposure to certain viruses, by testing
                                    for the presence of certain current virus <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, and by
                                    inactivating and removing certain viruses<span class="Italics">. </span>Despite these measures, such
                                    products can still potentially transmit disease. Because this
                                    product is made from human blood, it may carry a risk of
                                    transmitting infectious agents, e.g., viruses, and
                                    theoretically, the Creutzfeldt-Jakob disease (CJD) agent. This
                                    also applies to unknown or emerging viruses or other pathogens.
                                    All <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> thought by a physician possibly to have been
                                    transmitted by this product should be reported by the physician
                                    or other healthcare provider to Baxter Healthcare Corporation,
                                    telephone # 1-866-888-2472. </p>
<p>Some viruses,
                                    such as parvovirus B19, are particularly difficult to remove or
                                    inactivate at this time. Parvovirus B19 most seriously affects
                                    pregnant women (fetal <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>), immune-compromised individuals
                                    or individuals with an increased erythropoiesis (e.g., hemolytic
                                    <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>) (see <span class="Italics"><a href="#i4i_pregnancy_id_551d72ae-0a2c-4a33-860f-8a30eb448085">USE IN SPECIFIC POPULATIONS, Pregnancy (8.1)
                                        </a></span>and <span class="Italics"><a href="#i4i_info_patients_id_1f62d8d8-1944-4161-9c65-6b98385ab2ee">PATIENT COUNSELING INFORMATION
                                        (17)</a>).</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_17ac6258-3314-4087-9c9b-28637a29bca3"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First">The most frequent (≥ 1% of clinical study subjects) adverse
                            reactions with the use of ARTISS were: <span class="product-label-link" type="condition" conceptid="4308404" conceptname="Skin graft failure">skin graft failure</span>, <span class="product-label-link" type="condition" conceptid="4147001" conceptname="Hematoma">hematoma</span> and
                            <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span> in burn studies, and <span class="product-label-link" type="condition" conceptid="4147001" conceptname="Hematoma">hematoma</span>/<span class="product-label-link" type="condition" conceptid="4209136" conceptname="Seroma">seroma</span> in rhytidectomy
                            studies.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_daed8dbc-1210-4b01-83df-891c036d1daa"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trials Experience</h2>
<p class="First"><span class="Italics">Because clinical trials
                                        are conducted under widely varying conditions, adverse
                                        reaction rates observed in the clinical trials of a drug
                                        cannot be directly compared to rates in the clinical trials
                                        of another drug and may not reflect the rates observed in
                                        practice.</span></p>
<p style="border-left:1px solid;"><span class="XmChange">The burn and rhytidectomy surgery
                                        studies were prospective, randomized, controlled,
                                        multicenter clinical studies with a total of 298 subjects.
                                        In each study the subject served as its own control. All
                                        subjects treated have been included into the safety
                                        analysis. See <span class="Italics">CLINICAL STUDIES
                                            (14)</span> for
                                        outcome.</span></p>
<p style="border-left:1px solid;"><span class="XmChange">The data described in Table 2 reflects
                                        the exposure to ARTISS in the 4 burn and rhytidectomy
                                        surgery studies:</span></p>
<a name="id_c6a70336-d51d-4498-afe9-e102a9deebdc"></a><table border="single" width="554">
<caption><span>Table 2.
                                        Study Population Demographics</span></caption>
<col width="17.9%">
<col width="20.8%">
<col width="20.8%">
<col width="18.8%">
<col width="21.8%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" colspan="2" valign="top"><span class="Bold">Burn</span></td>
<td class="Botrule Rrule" align="center" colspan="2" valign="top"><span class="Bold">Rhytidectomy</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold">Parameter</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">Preliminary
                                                  Study</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">Confirmatory
                                                  Study</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">Preliminary
                                                  Study</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">Confirmatory
                                                  Study</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold">Sample size
                                                  (N)</span></td>
<td class="Botrule Rrule" align="center" valign="top">40</td>
<td class="Botrule Rrule" align="center" valign="top">138</td>
<td class="Botrule Rrule" align="center" valign="top">45</td>
<td class="Botrule Rrule" align="center" valign="top">75</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
<p class="First"><span class="Bold">Gender </span></p>
<p><span class="Bold">F (%)
                                                  /</span></p>
<span class="Bold">M
                                                  (%)</span>
</td>
<td class="Botrule Rrule" align="left" valign="top">
<p class="First">11 (27.5%) </p> 29
                                                (72.5%)</td>
<td class="Botrule Rrule" align="left" valign="top">
<p class="First">44 (31.9%) </p>94 (68.1%)</td>
<td class="Botrule Rrule" align="left" valign="top">
<p class="First">42 (93.3%)  </p>
<p>3
                                                  (6.7%)</p>
</td>
<td class="Botrule Rrule" align="left" valign="top">
<p class="First">71 (94.7%)  </p>4 (5.3%)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold">Age Range
                                                  (years)</span></td>
<td class="Botrule Rrule" align="left" valign="top">6 – 55 </td>
<td class="Botrule Rrule" align="left" valign="top">1 – 63 </td>
<td class="Botrule Rrule" align="left" valign="top">43 – 70 </td>
<td class="Botrule Rrule" align="left" valign="top">
                                                40 - 71</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">
<p class="First"><span class="Bold">Volume
                                                  applied</span></p>
<p><span class="Bold">(Mean ±
                                                  SD)</span></p>
<span class="Bold">(Range in mL)</span>
</td>
<td class="Rrule" align="left" valign="top">
<p class="First">2.9 ± 1.64 </p>(Range: 1.0 -
                                                10.8)</td>
<td class="Rrule" align="left" valign="top">
<p class="First">2.7 ± 1.9 </p>(Range: 0.2 -
                                                12.0)</td>
<td class="Rrule" align="left" valign="top">
<p class="First">2.32 ± 0.95 </p>(Range: 0.80 -
                                                4.0)</td>
<td class="Botrule Rrule" align="left" valign="top">
<p class="First">2.58 ± 1.17 </p>(Range: 0.60 -
                                                4.0)</td>
</tr>
</tbody>
</table>
<p>Adverse reactions in the burn studies occurring
                                    in greater than 1% of subjects treated with ARTISS were skin
                                    graft failure (3%), <span class="product-label-link" type="condition" conceptid="4147001" conceptname="Hematoma">hematoma</span> (1%) and <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span> (1%) [n=178].
                                        </p>
<p style="border-left:1px solid;"><span class="XmChange">Adverse
                                        reactions in the facial rhytidectomy studies occurring in
                                        greater than 1% of subjects treated with ARTISS were
                                        <span class="product-label-link" type="condition" conceptid="4147001" conceptname="Hematoma">hematoma</span>/<span class="product-label-link" type="condition" conceptid="4209136" conceptname="Seroma">seroma</span> (4%) [n =
                                        120].</span></p>
<p style="border-left:1px solid;"><span class="XmChange">In the facial rhytidectomy studies,
                                        three subjects experienced serious adverse events
                                        (experiences). Two were local: <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span> <span class="product-label-link" type="condition" conceptid="444202" conceptname="Abscess">abscess</span> on the ARTISS
                                        treated side of the face that was recognized on
                                        postoperative day 14 and was treated by operative incision
                                        and drainage; and a case of basal cell carcinoma on the SoC
                                        treated side of the face. A third subject experienced
                                        <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span> on the second postoperative day.
                                    </span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_74e83fe8-159a-4e36-8220-1a2777cda3c6"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Post-Marketing Experience</h2>
<p class="First"><span class="Italics">The following adverse
                                        reactions have been identified during post approval use of
                                        ARTISS. Because these reactions are reported voluntarily
                                        from a population of uncertain size, it is not always
                                        possible to reliably estimate their frequency or establish a
                                        causal relationship to drug
                                    exposure.</span></p>
<p>Fatal <span class="product-label-link" type="condition" conceptid="4156949" conceptname="Air embolism">air embolism</span> has
                                    been reported with misapplication of fibrin sealants
                                    administered with a pressurized spray
                                    device.</p>
<p>The following adverse reactions
                                    have been reported in post-marketing experience with another
                                    Baxter fibrin sealant that could reasonably be expected to occur
                                    with ARTISS:</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="440371" conceptname="Disorder of immune function">Immune system disorders</span></span>: anaphylactic responses,
                                    <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span></p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="321588" conceptname="Heart disease">Cardiac disorders</span></span>: <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>,
                                    <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span></p>
<p><span class="Bold">Respiratory, thoracic and <span class="product-label-link" type="condition" conceptid="440142" conceptname="Disorder of mediastinum">mediastinal disorders</span></span>:
                                    <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span></p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal disorders</span></span>:
                                        <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span></p>
<p><span class="Bold">Skin
                                        and subcutaneous tissue disorders</span>:
                                    <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span></p>
<p><span class="Bold">General disorders and administration site
                                        conditions</span>: <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, <span class="product-label-link" type="condition" conceptid="4304198" conceptname="Impaired tissue repair">impaired healing</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>,
                                    <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span></p>
<p><span class="Bold">Injury,
                                        <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span> and procedural complication</span>:
                                    <span class="product-label-link" type="condition" conceptid="4209136" conceptname="Seroma">seroma</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_interactions_id_aed39579-ab10-4875-bdf0-d5724b0add48"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<p class="First">Oxycellulose containing preparations may reduce the efficacy of
                            ARTISS and should not be used as carrier materials. No interaction
                            studies have been performed. </p>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="i4i_specific_populations_id_ac9e6c21-962d-4267-a64e-aecec898f117"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_551d72ae-0a2c-4a33-860f-8a30eb448085"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First"><span class="Bold">Pregnancy Category C</span></p>
<p>Animal reproduction studies have not been
                                    conducted with ARTISS. It is also not known whether ARTISS can
                                    cause fetal harm when administered to a pregnant woman or can
                                    affect reproduction capacity. Some viruses, such as parvovirus
                                    B19, are particularly difficult to remove or inactivate at this
                                    time. Parvovirus B19 most seriously affects pregnant women
                                    (fetal <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>)<span class="Italics">. </span>ARTISS
                                    should be given to a pregnant woman only if deemed medically
                                    necessary. </p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_d30a43bf-0183-4365-8338-1297d8641819"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">It is not known whether this drug is excreted in human
                                    milk. Because many drugs are excreted in human milk, caution
                                    should be exercised when ARTISS is administered to nursing
                                    mothers.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_1607068d-7e8d-4d6d-970e-b6b29a934e17"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">In two clinical trials utilizing ARTISS to adhere
                                    autologous skin grafts to surgically prepared <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span> beds
                                    resulting from <span class="product-label-link" type="condition" conceptid="4022094" conceptname="Thermal burn">burns</span>, the efficacy and safety of ARTISS in 38
                                    pediatric subjects (27 subjects ages 1 through 10 years and 11
                                    subjects ages 11 through 16 years) were not different from an
                                    adult population</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="i4i_geriatric_use_id_767f1ab1-0c9e-47c2-8302-4d561d8d2ffc"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">Thirteen subjects aged 65 and older (65 – 71 years of
                                    age) have been treated with ARTISS in facial rhytidectomy
                                    clinical studies. Separate evaluations of these subjects were
                                    not performed. </p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_b99c5d6a-ec12-4abb-98d4-7507f6043ba0"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">To avoid the formation of excess granulation tissue and to
                            ensure gradual absorption of the polymerized fibrin sealant, apply only
                            a thin layer of ARTISS (see <span class="Italics"><a href="#i4i_section_id_bb65e1de-0810-44be-997e-054ff07ecbdb">DOSAGE AND ADMINISTRATION, Method of Application
                                    (2.3)</a>).</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_c05b7b60-ff2d-4166-a71a-da6ee50ce2fd"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">ARTISS [Fibrin Sealant (Human)] is a two-component fibrin
                            sealant made from pooled human plasma. </p>
<p><span class="Bold">Sealer Protein (Human)</span></p>
<p>Sealer Protein (Human) is a sterile, non-pyrogenic,
                            vapor-heated and solvent/detergent treated preparation made from pooled
                            human plasma. Sealer Protein (Human) is provided either as a
                            freeze-dried powder [Sealer Protein Concentrate (Human)] for
                            reconstitution with <span class="product-label-link" type="condition" conceptid="4299457" conceptname="Fibrinolysis">Fibrinolysis</span> Inhibitor Solution (Synthetic) or as a
                            frozen liquid solution pre-filled into one side of a dual-chambered
                            syringe (1). The active ingredient in Sealer Protein (Human) is
                            fibrinogen. A <span class="product-label-link" type="condition" conceptid="4299457" conceptname="Fibrinolysis">Fibrinolysis</span> Inhibitor, Aprotinin (Synthetic) is included
                            in the Sealer Protein (Human) component to delay <span class="product-label-link" type="condition" conceptid="4299457" conceptname="Fibrinolysis">fibrinolysis</span>. Aprotinin
                            (Synthetic) is manufactured by solid phase synthesis from materials
                            completely of non-human/non-animal
                                origin.</p>
<p><span class="Bold">Thrombin
                                (Human)</span></p>
<p>Thrombin (Human) is a sterile, non-pyrogenic,
                            vapor-heated and solvent/detergent treated preparation made from pooled
                            human plasma. Thrombin (Human) is also provided either as a freeze-dried
                            powder for reconstitution with Calcium Chloride Solution or as a frozen
                            liquid solution pre-filled into one side of a dual-chambered syringe
                            (2). </p>
<p>Sealer Protein (Human) and Thrombin (Human)
                            are made from pooled human plasma collected at US licensed collection
                            centers. The vapor heat and solvent/detergent treatment steps used in
                            the manufacturing process have been shown to be capable of significant
                            viral reduction. No procedure, however, has been shown to be completely
                            effective in removing viral infectivity from derivatives of human plasma
                            (see <span class="Italics">Viral Clearance
                                below</span><span class="Italics"> and </span><span class="Italics"><a href="#i4i_section_id_8535bc13-2899-4367-9f7b-4e292f8b891d">WARNINGS/PRECAUTIONS, <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span> Risk from Human Plasma
                                    (5.4)</a></span>.</p>
<p><span class="Bold">Viral
                                Clearance </span></p>
<p>The manufacturing
                            procedure for ARTISS includes processing steps designed to further
                            reduce the risk of viral transmission. In particular, vapor heating and
                            solvent/detergent treatment processes are included in the manufacturing
                            of Sealer Protein Concentrate and Thrombin. Validation studies were
                            conducted using samples drawn from manufacturing intermediates for each
                            of the two human plasma derived components. These samples were spiked
                            with stock virus suspensions of known titers followed by further
                            processing under conditions equivalent to those in the respective
                            manufacturing steps. The stock virus suspensions represent HIV, HBV,
                            HCV, HAV and Human Parvovirus B19. </p>
<p>The virus
                            reduction factors (expressed as log<span class="Sub">10</span>) of independent
                            manufacturing steps are shown in Table 3 for each of the viruses
                            tested:</p>
<a name="id_ced8e21f-a9b8-4f7b-887b-81bc614913de"></a><table border="single" width="551">
<caption><span>Table 3. Reduction
                                Factors for Virus Removal and/or Inactivation</span></caption>
<col width="36.8%">
<col width="13.1%">
<col width="12.0%">
<col width="12.0%">
<col width="12.0%">
<col width="14.0%">
<tfoot><tr><td colspan="6" align="left"><dl class="Footnote">
<dt><a name="footnote-2" href="#footnote-reference-2">*</a></dt>
<dd>
<span class="Bold">HIV-1</span>: Human
                                            <span class="product-label-link" type="condition" conceptid="433740" conceptname="Immunodeficiency disorder">immunodeficiency</span> virus 1; <span class="Bold">HAV</span>: <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span> A virus; <span class="Bold">BVDV</span>: Bovine viral
                                            <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> virus, a model for <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span> C virus; <span class="Bold">PRV</span>: Pseudorabies virus,
                                            a model for enveloped DNA viruses, among those <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span>
                                            B virus; <span class="Bold">MMV</span>: Mice
                                            minute virus, a model for B19V.</dd>
<dt><a name="footnote-3" href="#footnote-reference-3">†</a></dt>
<dd>n.d. = not
                                            determined</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First"><td class="Lrule Rrule" align="center" colspan="6" valign="top"><span class="Bold">Reduction Factors for
                                            Virus Removal and/or Inactivation<br>Sealer Protein
                                            Component</span></td></tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" rowspan="2" valign="bottom">Manufacturing Step</td>
<td class="Botrule Rrule" align="center" colspan="5" valign="middle">Mean Reduction Factors [log<span class="Sub">10</span>] of
                                        Virus Tested</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="middle">HIV-1<a name="footnote-reference-2" href="#footnote-2" class="Sup">*</a>
</td>
<td class="Botrule Rrule" align="center" valign="middle">HAV<a href="#footnote-2" class="Sup">*</a>
</td>
<td class="Botrule Rrule" align="center" valign="middle">BVDV<a href="#footnote-2" class="Sup">*</a>
</td>
<td class="Botrule Rrule" align="center" valign="middle">PRV<a href="#footnote-2" class="Sup">*</a>
</td>
<td class="Botrule Rrule" align="center" valign="middle">MMV<a href="#footnote-2" class="Sup">*</a>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">Early Manufacturing Steps</td>
<td class="Botrule Rrule" align="center" valign="middle">n.d.<a name="footnote-reference-3" href="#footnote-3" class="Sup">†</a>
</td>
<td class="Botrule Rrule" align="center" valign="middle">n.d.</td>
<td class="Botrule Rrule" align="center" valign="middle">n.d.</td>
<td class="Botrule Rrule" align="center" valign="middle">n.d.</td>
<td class="Botrule Rrule" align="center" valign="middle">2.7</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">Solvent/Detergent Treatment</td>
<td class="Botrule Rrule" align="center" valign="middle">&gt;5.3</td>
<td class="Botrule Rrule" align="center" valign="middle">n.d.</td>
<td class="Botrule Rrule" align="center" valign="middle">&gt;5.7</td>
<td class="Botrule Rrule" align="center" valign="middle">&gt;5.9</td>
<td class="Botrule Rrule" align="center" valign="middle">n.d.</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">Vapor Heat Treatment</td>
<td class="Botrule Rrule" align="center" valign="middle">&gt;5.5</td>
<td class="Botrule Rrule" align="center" valign="middle">&gt;5.6</td>
<td class="Botrule Rrule" align="center" valign="middle">&gt;5.7</td>
<td class="Botrule Rrule" align="center" valign="middle">&gt;6.7</td>
<td class="Botrule Rrule" align="center" valign="middle">1.2</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">Overall Reduction Factor (ORF)</td>
<td class="Botrule Rrule" align="center" valign="middle">&gt;10.8</td>
<td class="Botrule Rrule" align="center" valign="middle">&gt;5.6</td>
<td class="Botrule Rrule" align="center" valign="middle">&gt;11.4</td>
<td class="Botrule Rrule" align="center" valign="middle">&gt;12.6</td>
<td class="Botrule Rrule" align="center" valign="middle">3.9</td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="center" colspan="6" valign="top"><span class="Bold">Reduction Factors for
                                            Virus Removal and/or Inactivation<br>Thrombin
                                            Component</span></td></tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="middle"></td>
<td class="Botrule Rrule" align="center" colspan="5" valign="middle">Mean Reduction Factors [log<span class="Sub">10</span>] of
                                        Virus Tested</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="middle">Manufacturing Step</td>
<td class="Botrule Rrule" align="center" valign="middle">HIV-1</td>
<td class="Botrule Rrule" align="center" valign="middle">HAV</td>
<td class="Botrule Rrule" align="center" valign="middle">BVDV</td>
<td class="Botrule Rrule" align="center" valign="middle">PRV</td>
<td class="Botrule Rrule" align="center" valign="middle">MMV</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">Thrombin precursor <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span> capture</td>
<td class="Botrule Rrule" align="center" valign="middle">3.2</td>
<td class="Botrule Rrule" align="center" valign="middle">1.5</td>
<td class="Botrule Rrule" align="center" valign="middle">1.8</td>
<td class="Botrule Rrule" align="center" valign="middle">2.5</td>
<td class="Botrule Rrule" align="center" valign="middle">1.2</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">Vapor Heat Treatment</td>
<td class="Botrule Rrule" align="center" valign="middle">&gt;5.5</td>
<td class="Botrule Rrule" align="center" valign="middle">&gt;4.9 </td>
<td class="Botrule Rrule" align="center" valign="middle">&gt;5.3</td>
<td class="Botrule Rrule" align="center" valign="middle">&gt;6.7</td>
<td class="Botrule Rrule" align="center" valign="middle">1.0</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">Solvent/Detergent Treatment</td>
<td class="Botrule Rrule" align="center" valign="middle">&gt;5.3</td>
<td class="Botrule Rrule" align="center" valign="middle">n.d.</td>
<td class="Botrule Rrule" align="center" valign="middle">&gt;5.5</td>
<td class="Botrule Rrule" align="center" valign="middle">&gt;6.4</td>
<td class="Botrule Rrule" align="center" valign="middle">n.d.</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">Ion Exchange Chromatography</td>
<td class="Botrule Rrule" align="center" valign="middle">n.d.</td>
<td class="Botrule Rrule" align="center" valign="middle">n.d.</td>
<td class="Botrule Rrule" align="center" valign="middle">n.d.</td>
<td class="Botrule Rrule" align="center" valign="middle">n.d.</td>
<td class="Botrule Rrule" align="center" valign="middle">3.6</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="middle">Overall Reduction Factor (ORF)</td>
<td class="Rrule" align="center" valign="middle">&gt;14.0</td>
<td class="Rrule" align="center" valign="middle">&gt;6.4</td>
<td class="Rrule" align="center" valign="middle">&gt;12.6</td>
<td class="Rrule" align="center" valign="middle">&gt;15.6</td>
<td class="Botrule Rrule" align="center" valign="middle">5.8</td>
</tr>
</tbody>
</table>
<p>In addition, Human Parvovirus B19 was used to investigate
                            the upstream Thrombin precursor <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span> capture step, the Sealer Protein
                            early manufacturing steps and the Thrombin and Sealer Protein vapor
                            heating steps. Using quantitative PCR assays, the estimated log
                            reduction factors obtained were 1.7 and 3.4 for the Thrombin precursor
                            <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span> capture step and Sealer Protein early manufacturing steps and &gt;4
                            / 1.0 for the Thrombin / Sealer Protein vapor heating steps,
                            respectively.</p>
<p>See <span class="Italics">DOSAGE FORMS AND STRENGTHS (<a href="#i4i_dosage_form_strength_id_22ad3d16-2cb7-4985-a242-c8fe3407d5b0">3</a>).</span></p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_41fde129-3479-49e8-ba7f-7d4c39a3a411"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="i4i_mechanism_action_id_8f8a73d5-ca91-4085-a157-720454675359"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">Upon mixing Sealer Protein (Human) and Thrombin
                                    (Human), the two components mimic the final stage of the blood
                                    coagulation cascade. Soluble fibrinogen is transformed into
                                    fibrin that adheres to the <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span> surface and to the skin flap or
                                    graft to be affixed. Due to the low thrombin concentration,
                                    initial polymerization of ARTISS will take up to 60 seconds. The
                                    fibrin clot continues to strengthen for up to 2 hours after
                                    application. </p>
<p>Spray application of ARTISS
                                    over the <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span> bed provides full surface adherence of skin flaps
                                    and grafts. Full surface adherence minimizes areas of dead space
                                    between the <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span> bed and applied tissues. Elimination of dead
                                    space prevents shear irritation upon movement as well as reduces
                                    the void space under the skin that can host fluid
                                    build-up.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="i4i_pharmacodynamics_id_b1960226-b6dc-4340-9bbb-6426279bc329"></a><a name="section-11.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<p class="First">Thrombin is a highly specific protease that transforms
                                    the fibrinogen contained in Sealer Protein (Human) into
                                        fibrin<span class="Italics"> (see <a href="#i4i_pharmacokinetics_id_2b2d06a4-7b37-4a39-b7e2-b87a29926801">Pharmacokinetics (12.3)</a>).
                                    </span></p>
<p><span class="product-label-link" type="condition" conceptid="4299457" conceptname="Fibrinolysis">Fibrinolysis</span> Inhibitor,
                                    Aprotinin (Synthetic), is a polyvalent protease inhibitor that
                                    prevents premature degradation of fibrin. Free Aprotinin and its
                                    metabolites have a half-life of 30 to 60 minutes and are
                                    eliminated by the kidney. Preclinical studies with different
                                    fibrin sealant preparations simulating the fibrinolytic activity
                                    generated by extracorporeal circulation in patients during
                                    cardiovascular surgery have shown that incorporation of
                                    aprotinin in the product formulation increases resistance of the
                                    fibrin sealant clot to degradation in a fibrinolytic
                                    environment. </p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="i4i_pharmacokinetics_id_2b2d06a4-7b37-4a39-b7e2-b87a29926801"></a><a name="section-11.3"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First">Pharmacokinetic studies were not conducted. Because
                                    ARTISS is applied only topically, systemic exposure or
                                    distribution to other organs or tissues is not expected.
                                </p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="i4i_nonclinical_toxicology_id_48e6da41-db51-4581-9a57-56f9329a9cc3"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_f3fc225c-96db-46c8-b325-66e669cfff5d"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Long-term animal studies to evaluate the carcinogenic
                                    potential of ARTISS or studies to determine the effect of ARTISS
                                    on fertility have not been performed.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="i4i_clinical_studies_id_3975c971-cdf2-43b7-b04f-f32c23b575f1"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<div class="Section" data-sectionCode="34092-7">
<a name="i4i_clinical_studies_duplicate_id_6976e8fc-9b68-47b0-b1f6-9c6f0010ea48"></a><a name="section-13.1"></a><p></p>
<h2>14.1 <span class="product-label-link" type="condition" conceptid="4022094" conceptname="Thermal burn">Burns</span> (grafts)</h2>
<p class="First">ARTISS was investigated for adherence of split
                                    thickness sheet skin grafts in burn patients in a prospective,
                                    randomized, controlled, evaluator- blinded, multicenter clinical
                                    study. In each of the 138 patients, two comparable test sites
                                    were identified after burn <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span> excision. Skin grafts were
                                    adhered at one test site using ARTISS, and at the other test
                                    site using staples (control). The study product was applied once
                                    to the <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span> bed of the allocated test site during skin grafting
                                    surgery. </p>
<p>The mean ± SD estimated total
                                    body surface area (TBSA) for all burn <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wounds</span> was 13.6 ± 9.2%.
                                    The mean ± SD estimated TBSA requiring skin grafting was 8.0 ±
                                    6.9%. The mean ± SD estimated TBSA for ARTISS test sites was 1.7
                                    ± 0.8% and for the stapled test sites was 1.7 ± 0.7%. Burn <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span>
                                    thickness was classified as full thickness in 106 (76.8%) of the
                                    138 treated subjects, and partial thickness in 32 (23.2%)
                                    subjects.</p>
<p>The safety population contained
                                    all 138 treated subjects; however, 11 subjects did not have an
                                    available primary endpoint assessment, leaving a modified
                                    intent-to-treat (ITT) set of 127 patients. Complete <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span>
                                    closure by Day 28 was achieved in 43.3% of the ARTISS test sites
                                    and 37.0% of the stapled test sites in the 127 ITT patients.
                                    <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">Wound</span> closure at Day 28 was complete at 72% of the ARTISS and
                                    staples test sites for the 1-?6 years old group (N=18), at 32%
                                    of the ARTISS test sites and 26% of the staples test sites for
                                    the 7-18 years old group (N=19) and at 40% of the ARTISS test
                                    sites and 32% of the staples test sites for the greater then 18
                                    years old group [ITT]. The lower limit of the 97.5% confidence
                                    interval of the difference between ARTISS and staples was
                                    –0.029. A similar result was obtained in the per protocol (PP)
                                    population: complete <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span> closure by Day 28 was achieved in
                                    45.3% of the ARTISS test sites and 39.6% of the stapled test
                                    sites in the 106 PP patients. The lower limit of the 97.5%
                                    confidence interval of the difference between ARTISS and staples
                                    was –0.041. Therefore, ARTISS was found to be non-inferior to
                                    staples in the ITT and PP populations at the 97.5% one-sided
                                    level for complete <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span> closure by Day 28 because the lower
                                    limit of the confidence interval of the difference between
                                    ARTISS and staples success rates was greater than the predefined
                                    limit of –0.1.</p>
<p><span class="Bold">14.2 Facial Rhytidectomy
                                    (flaps)</span></p>
<p>ARTISS was investigated
                                    for adherence of skin flaps in facial rhytidectomy surgeries
                                    during two prospective, randomized, controlled, multicenter
                                    clinical studies. Both the preliminary study investigating 45
                                    subjects and the confirmatory study with 75 subjects had a
                                    split-face design in which 1 side of the face was treated with
                                    ARTISS as an adjunct to the standard of care (SoC) and the other
                                    side received SoC only, which was closure of the flap by means
                                    of staples and suturing only; therefore each subject
                                    participated in both arms (ARTISS and SoC).
                                    </p>
<p>Primary endpoint of the confirmatory
                                    study conducted in 75 subjects was the total drainage volume
                                    collected from each side of the face at 24 h (±4 h) post
                                    surgery. Occurrence of <span class="product-label-link" type="condition" conceptid="4147001" conceptname="Hematoma">hematoma</span> and <span class="product-label-link" type="condition" conceptid="4209136" conceptname="Seroma">seroma</span> on each side of the
                                    face, comparison of <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> between the 2 sides of the face,
                                    changes in skin sensitivity from baseline on each side of the
                                    face and subject preference were evaluated as secondary
                                    endpoints.</p>
<p>In both studies, a standardized
                                    drain was placed in each side of the face prior to the flap
                                    closure and drainage volume from both sides of the face from all
                                    subjects was compared. Pressure dressings were not allowed.
                                    </p>
<p>The results for the primary endpoint of
                                    the confirmatory study are presented in<a href="#id_66e3f89f-8c84-417d-b22a-b9124161f4b2"> Table
                                        4a</a> below. </p>
<a name="id_66e3f89f-8c84-417d-b22a-b9124161f4b2"></a><table border="none" width="538">
<caption><span>Table 4a.
                                        Drainage Volume Comparison at 24 h Post Operative in
                                        Confirmatory Study</span></caption>
<col width="21.4%">
<col width="34.8%">
<col width="27.5%">
<col width="16.4%">
<tbody class="Headless">
<tr class="First Toprule">
<td align="center" valign="top"><span class="Bold">Clinical Study (n=
                                                75)</span></td>
<td class="Toprule" align="center" valign="top"><span class="Bold">Mean ± SD Drainage (mL)
                                                  ARTISS Side of the Face</span></td>
<td class="Toprule" align="center" valign="top"><span class="Bold">Mean ± SD Drainage (mL)
                                                  SoC Side of the Face</span></td>
<td align="center" valign="top"><span class="Bold">p-Value</span></td>
</tr>
<tr class="Botrule Last">
<td align="center" valign="top">Confirmatory study</td>
<td align="center" valign="top">7.7 ± 7.4</td>
<td align="center" valign="top">20.0 ± 11.3</td>
<td align="center" valign="top">&lt; 0.0001</td>
</tr>
</tbody>
</table>
<p> </p>
<p>A statistically
                                    significant difference in drainage volumes was observed,
                                    favoring the side of the face treated with ARTISS.
                                    </p>
<p>Drainage volumes at 24 h post operatively
                                    for each side of the face reported as secondary endpoint in the
                                    preliminary study are presented in <a href="#id_3d32e098-481f-40a7-9e76-3ea08d9ff1c6">Table
                                        4b</a> below.</p>
<a name="id_3d32e098-481f-40a7-9e76-3ea08d9ff1c6"></a><table border="single" width="413">
<caption><span>Table 4b.
                                        Drainage Volume Comparison at 24 h Post Operative in
                                        Preliminary Study</span></caption>
<col width="33.3%">
<col width="33.3%">
<col width="33.3%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><span class="Bold">Clinical
                                                  Study (n = 45)</span></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Bold">Mean ± SD
                                                  Drainage (mL) ARTISS Side of the
                                                Face</span></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Bold">Mean ± SD
                                                  Drainage (mL) SoC Side of the Face</span></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="center" valign="middle">Preliminary study</td>
<td class="Rrule" align="center" valign="middle">11.5 ± 13.7</td>
<td class="Botrule Rrule" align="center" valign="middle">26.8 ± 24.0</td>
</tr>
</tbody>
</table>
<p> </p>
<p>An integrated analysis of
                                    the occurrence of <span class="product-label-link" type="condition" conceptid="4147001" conceptname="Hematoma">hematoma</span>/<span class="product-label-link" type="condition" conceptid="4209136" conceptname="Seroma">seroma</span> in all 120 subjects across two
                                    studies was performed. A comparison of the proportion of
                                    subjects experiencing a <span class="product-label-link" type="condition" conceptid="4147001" conceptname="Hematoma">hematoma</span>/<span class="product-label-link" type="condition" conceptid="4209136" conceptname="Seroma">seroma</span> exclusively on the
                                    ARTISS-treated side or on the SoC side of the face is presented
                                    in Table 5 below.   </p>
<a name="id_c6b632b5-1cbc-4f27-88ab-24c051db6665"></a><table border="single" width="443">
<caption><span>Table 5.
                                        Occurrence of <span class="product-label-link" type="condition" conceptid="4147001" conceptname="Hematoma">Hematoma</span> / <span class="product-label-link" type="condition" conceptid="4209136" conceptname="Seroma">Seroma</span></span></caption>
<col width="39.1%">
<col width="17.0%">
<col width="15.7%">
<col width="13.5%">
<col width="14.5%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><span class="Bold">Clinical
                                                  Study</span></td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First"><span class="Bold">ARTISS</span></p>
<span class="Bold">n (%)</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First"><span class="Bold">SoC</span></p>
<span class="Bold">n (%)</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First"><span class="Bold">Both Sides of Face</span></p>
<span class="Bold">n (%)</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First"><span class="Bold">Total </span></p>
<span class="Bold">n (%)</span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top">Preliminary study</td>
<td class="Botrule Rrule" align="center" valign="top">0</td>
<td class="Botrule Rrule" align="center" valign="middle">9 (20%)</td>
<td class="Botrule Rrule" align="center" valign="middle">0</td>
<td class="Botrule Rrule" align="center" valign="middle">9 (20%)</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="center" valign="top">Confirmatory study</td>
<td class="Rrule" align="center" valign="top">2
                                                (2.7%)</td>
<td class="Rrule" align="center" valign="middle">5
                                                (6.7%)</td>
<td class="Rrule" align="center" valign="middle">3
                                                (4%)</td>
<td class="Botrule Rrule" align="center" valign="middle">10 (13.3%)</td>
</tr>
</tbody>
</table>
<p> </p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_a17a60e1-d930-48e4-b1a9-17c39e0208d4"></a><a name="section-14"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">ARTISS is supplied in the following pack sizes and
                            presentations:</p>
<a name="id_11a049d8-ccdb-4de9-9c69-80d0e16b5518"></a><table width="600.000">
<caption><span>Table 6. NDC
                                Numbers</span></caption>
<col align="center" width="10.0%">
<col align="center" width="30.0%">
<col align="center" width="30.0%">
<col align="center" width="30.0%">
<thead>
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" rowspan="2" valign="middle"><span class="Bold">Pack Size</span></td>
<td class="Botrule Rrule" align="center" colspan="3" valign="middle"><span class="Bold">NDC
                                            Number</span></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="center" valign="middle"><span class="Bold">ARTISS Kit
                                            (Freeze-Dried)</span></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Bold">ARTISS Kit (Freeze-Dried)
                                            with DUPLOJECT System</span></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Bold">ARTISS Pre-Filled Syringe
                                            (Frozen) with DUO Set</span></td>
</tr>
</thead>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">2 mL</td>
<td class="Botrule Rrule" align="center" valign="middle">0944-4351-03</td>
<td class="Botrule Rrule" align="center" valign="middle">0944-4351-04</td>
<td class="Botrule Rrule" align="center" valign="middle">0944-8503-02</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="middle">4 mL</td>
<td class="Botrule Rrule" align="center" valign="middle">0944-4351-07</td>
<td class="Botrule Rrule" align="center" valign="middle">0944-4351-08</td>
<td class="Botrule Rrule" align="center" valign="middle">0944-8503-04</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="center" valign="middle">10 mL</td>
<td class="Rrule" align="center" valign="middle">0944-4351-11</td>
<td class="Rrule" align="center" valign="middle">0944-4351-12</td>
<td class="Botrule Rrule" align="center" valign="middle">0944-8503-10</td>
</tr>
</tbody>
</table>
<p>See<span class="Italics"><a href="#i4i_dosage_form_strength_id_22ad3d16-2cb7-4985-a242-c8fe3407d5b0"> DOSAGE FORMS AND STRENGTHS (3)</a></span>.</p>
<div class="Section" data-sectionCode="44425-7">
<a name="i4i_storage_id_d8627ae5-f907-49e3-8f07-f0f2cb699491"></a><a name="section-14.1"></a><p></p>
<p class="First"><span class="Bold">Storage</span></p>
<p>Store ARTISS in original carton to protect
                                    from light. Do not use after the expiration date. Discard if
                                    packaging of any components is
                                        damaged.</p>
<p><span class="Bold">ARTISS Kit (Freeze-Dried)</span></p>
<p>Store at 2°C to 25°C. Avoid freezing. After
                                    reconstitution, the product must be used within 4 hours.
                                    Reconstituted solutions must not be refrigerated or
                                    frozen.</p>
<p><span class="Bold">ARTISS Pre-filled Syringe
                                        (Frozen)</span></p>
<a name="id_8889917d-8351-4906-91d3-0fbe9495f781"></a><table width="600.000">
<col align="left" width="15.2%">
<col align="left" width="84.8%">
<tbody class="Headless">
<tr class="First">
<td class="Toprule" align="left" valign="top">Long
                                                term:</td>
<td align="left" valign="top">Store at ≤ -20°C.</td>
</tr>
<tr>
<td align="left" valign="top">Short term:</td>
<td align="left" valign="top">Room Temperature Thawing:
                                                Unopened pouches, thawed at room temperature, may be
                                                stored for up to 14 days at room temperature
                                                (15-25°C) after removal from the freezer.</td>
</tr>
<tr>
<td align="left" valign="top"></td>
<td align="left" valign="top">Quick Thawing: Maintain
                                                the product at 33-37°C until use. If the product is
                                                removed from original pouch or warmed to 33-37°C it
                                                must be used within 12 hours.</td>
</tr>
<tr class="Last">
<td class="Botrule" align="left" valign="top"></td>
<td class="Botrule" align="left" valign="top"><span class="Bold">Do not refrigerate or
                                                  re-freeze after thawing. Do not
                                                  microwave.</span></td>
</tr>
</tbody>
</table>
<p>Do not use after the expiration date. Discard if
                                    packaging of any components is damaged.</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_id_1f62d8d8-1944-4161-9c65-6b98385ab2ee"></a><a name="section-15"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First">Inform patients that ARTISS is made from human plasma and
                            discuss the risks and benefits with the patient.
                            </p>
<p>Parvovirus B19 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> may be serious for
                            pregnant women (fetal <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>) and for individuals with
                            <span class="product-label-link" type="condition" conceptid="433740" conceptname="Immunodeficiency disorder">immunodeficiency</span> or increased red blood cell turnover. Instruct patients
                            to consult their physician if symptoms of B19 virus <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> appear
                            (<span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span> and <span class="product-label-link" type="condition" conceptid="4170297" conceptname="Sniffles">runny nose</span> followed about two weeks later
                            by a <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> and <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">joint pain</span><span class="Italics"> (see USE IN
                                SPECIFIC POPULATIONS, Pregnancy (<a href="#i4i_pregnancy_id_551d72ae-0a2c-4a33-860f-8a30eb448085">8.1</a>)).</span></p>
<p><span class="Bold">Baxter Healthcare Corporation</span><br>Westlake Village, CA 91362 USA<br>US License No.
                            140</p>
<p>This product is covered under US Patent Nos.
                            5,962,405 and 6,579,537.</p>
<p>Baxter, Artiss,
                            Easyspray, Fibrinotherm and Duploject are trademarks of Baxter
                            International</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_45b1c4ba-1e6e-432b-b09c-2b8da0222136"></a><a name="section-16"></a><p></p>
<h1>Principal Display Panel</h1>
<div class="Figure">
<img alt="ARTISS 4 mL kit unit carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=38a6412e-9557-45ad-a917-da15109657ec&amp;name=906c38fb-0400-4440-8cc8-de27b2836640-02.jpg"><p class="MultiMediaCaption">ARTISS 4 mL kit
                                unit carton</p>
</div>
<p class="First">NDC 0944-4351-07</p>
<p>4
                            mL</p>
<p>Kit</p>
<p>Fibrin Sealant
                            (Human)</p>
<p>ARTISS</p>
<p>Contents:</p>
<p>Sealer
                            Protein Concentrate (Human). Vapor Heated, Solvent/Detergent Treated,
                            freeze dried, sterile, for 2 mL of Sealer Protein
                            Solution</p>
<p><span class="product-label-link" type="condition" conceptid="4299457" conceptname="Fibrinolysis">Fibrinolysis</span> Inhibitor Solution
                            (Synthetic), Sterile, 3000 KIU of
                            Aprotinin/mL</p>
<p>Thrombin (Human), Vapor Heated,
                            Solvent/Detergent Treated, freeze dried, sterile, for 2 mL of Thrombin
                            Solution 4 IU/mL</p>
<p>Calcium Chloride Solution.
                            Sterile, 40 µmol/mL</p>
<p><span class="Bold">FOR
                                TOPICAL USE ONLY</span></p>
<p><span class="Bold">NOT FOR
                            INJECTION</span></p>
<p>Do not use on individuals with
                            a know <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to aprotinin. The risk and benefits of this
                            product should be discussed with the patient. Read the full prescribing
                            information before use. </p>
<p>For single use
                            only.</p>
<p>No preservative</p>
<p>Latex
                            free</p>
<p>Rx Only</p>
<p>Baxter
                            </p>
<div class="Figure">
<img alt="ARTISS 4 mL kit sleeve" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=38a6412e-9557-45ad-a917-da15109657ec&amp;name=906c38fb-0400-4440-8cc8-de27b2836640-03.jpg"><p class="MultiMediaCaption">ARTISS 4 mL kit
                                sleeve</p>
</div>
<p>NDC 0944-4351-08</p>
<p>4
                            mL</p>
<p>Kit</p>
<p>Fibrin Sealant
                            (Human)</p>
<p>ARTISS</p>
<p>Contents:</p>
<p>Sealer
                            Protein Concentrate (Human). Vapor Heated, Solvent/Detergent Treated,
                            freeze dried, sterile, for 2 mL of Sealer Protein
                            Solution</p>
<p><span class="product-label-link" type="condition" conceptid="4299457" conceptname="Fibrinolysis">Fibrinolysis</span> Inhibitor Solution
                            (Synthetic), Sterile, 3000 KIU of
                            Aprotinin/mL</p>
<p>Thrombin (Human), Vapor Heated,
                            Solvent/Detergent Treated, freeze dried, sterile, for 2 mL of Thrombin
                            Solution 4 IU/mL</p>
<p>Calcium Chloride Solution.
                            Sterile, 40 µmol/mL</p>
<p>Also includes: DUPLOJECT
                            System for ARTISS [Fibrin Sealant (Human)]
                            2mL/4mL</p>
<p>FOR TOPICAL USE
                            ONLY</p>
<p>NOT FOR INJECTION</p>
<p>Do
                            not use on individuals with a know <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to aprotinin. The
                            risk and benefits of this product should be discussed with the patient.
                            Read the full prescribing information before use.
                            </p>
<p>For single use only.</p>
<p>No
                            preservative</p>
<p>Latex free</p>
<p>Rx
                            Only</p>
<p>Baxter </p>
<div class="Figure">
<img alt="Sealer Protein Concentrate vial label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=38a6412e-9557-45ad-a917-da15109657ec&amp;name=906c38fb-0400-4440-8cc8-de27b2836640-04.jpg"><p class="MultiMediaCaption">Sealer Protein
                                Concentrate (Human) vial label</p>
</div>
<p>NDC 0944-7112-02</p>
<p>Sealer
                            Protein Concentrate
                            (Human)</p>
<p>Baxter</p>
<p>Vapor Heated,
                            Solvent/Detergent Treated, Freeze-Dried, Sterile
                            </p>
<p>Reconstitute with 2 mL of <span class="product-label-link" type="condition" conceptid="4299457" conceptname="Fibrinolysis">Fibrinolysis</span> Inhibitor
                            Solution (Synthetic)</p>
<p>Vial contains a stirrer to
                            facilitate reconstitution.</p>
<p>Baxter Healthcare
                            Corporation</p>
<p>Westlake Village, CA 91362
                            USA</p>
<p>U.S. License No. 140</p>
<p>Use
                            within 4 hours of reconstitution.</p>
<p>Read enclosed
                            directions prior to use.</p>
<p>NOT FOR
                            INJECTION.</p>
<p>Store at 2ºC to
                            25ºC.</p>
<p>Rx only</p>
<div class="Figure">
<img alt="Thrombin Solution vial label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=38a6412e-9557-45ad-a917-da15109657ec&amp;name=906c38fb-0400-4440-8cc8-de27b2836640-05.jpg"><p class="MultiMediaCaption">Thrombin (Human)
                                vial label</p>
</div>
<p>NDC
                            0944-7344-02</p>
<p>Thrombin
                            (Human)</p>
<p>Baxter </p>
<p>Vapor
                            Heated, Solvent/Detergent Treated, Freeze-Dried,
                            Sterile</p>
<p>Reconstitute with 2 mL of Calcium Chloride
                            Solution</p>
<p>Concentration: 4
                            IU/mL</p>
<p>Baxter Healthcare
                            Corporation</p>
<p>Westlake Village, CA 91362
                            USA</p>
<p>U.S. License No. 140</p>
<p>Rx
                            Only</p>
<div class="Figure">
<img alt="Calcium Chloride vial label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=38a6412e-9557-45ad-a917-da15109657ec&amp;name=906c38fb-0400-4440-8cc8-de27b2836640-06.jpg"><p class="MultiMediaCaption">Calcium Chloride
                                Solution vial label</p>
</div>
<p>NDC 0944-7401-02</p>
<p>Calcium
                            Chloride Solution </p>
<p>Baxter
                            </p>
<p>Sterile For reconstitution of freeze-dried
                            Thrombin (Human), Contents: 2 mL </p>
<p>Concentration:
                            40 µmol/mL</p>
<p><span class="Bold">NOT FOR
                                INJECTION</span>. Store at 2°C to
                            25°C.</p>
<p>Baxter Healthcare
                            Corporation</p>
<p>Westlake Village, CA 91362
                            USA</p>
<p>U.S. License No. 140</p>
<p>Rx
                            Only</p>
<div class="Figure">
<img alt="<span class="product-label-link" type="condition" conceptid="4299457" conceptname="Fibrinolysis">Fibrinolysis</span> Inhibitor vial label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=38a6412e-9557-45ad-a917-da15109657ec&amp;name=906c38fb-0400-4440-8cc8-de27b2836640-07.jpg"><p class="MultiMediaCaption"><span class="product-label-link" type="condition" conceptid="4299457" conceptname="Fibrinolysis">Fibrinolysis</span>
                                Inhibitor Solution (Synthetic) vial label</p>
</div>
<p>NDC
                            0944-7201-01</p>
<p><span class="product-label-link" type="condition" conceptid="4299457" conceptname="Fibrinolysis">Fibrinolysis</span> Inhibitor Solution
                            (Synthetic)</p>
<p>Baxter </p>
<p>Sterile
                            For reconstitution of freeze-dried Sealer Protein Concentrate (Human),
                            Contents: 1 mL</p>
<p>Concentration: 3000 KIU of
                            Aprotinin/mL</p>
<p>NOT FOR INJECTION. Store at 2°C to
                            25°C.</p>
<p>Baxter Healthcare
                            Corporation</p>
<p>Westlake Village, CA 91362
                            USA</p>
<p>U.S. License No. 140</p>
<p>Rx
                            Only</p>
<div class="Figure">
<img alt="ARTISS 2 mL and 4 mL DUPLOJECT unit carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=38a6412e-9557-45ad-a917-da15109657ec&amp;name=906c38fb-0400-4440-8cc8-de27b2836640-08.jpg"><p class="MultiMediaCaption">ARTISS 2 mL and 4
                                mL DUPLOJECT unit carton</p>
</div>
<p>DUPLOJECT 2 mL / 4
                            mL</p>
<p>Preparation and Application System for ARTISS
                            [Fibrin Sealant (Human)]</p>
<p>For the preparation and
                            application of ARTISS [Fibrin Sealant (Human)] 2 mL/4mL
                            Kit.</p>
<p>STERILE - SINGLE PATIENT USE ONLY - DO NOT
                            RESTERILIZE</p>
<p>Use separate devices for
                            reconstitution of Sealer Protein Concentrate and
                            Thrombin.</p>
<p>Rx
                            only</p>
<p>Baxter</p>
<div class="Figure">
<img alt="ARTISS Frozen 4 mL unit carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=38a6412e-9557-45ad-a917-da15109657ec&amp;name=906c38fb-0400-4440-8cc8-de27b2836640-09.jpg"><p class="MultiMediaCaption">ARTISS Frozen 4 mL
                                unit carton</p>
</div>
<p>NDC 0944-8503-04</p>
<p>4
                            mL</p>
<p>Fibrin Sealant
                            (Human)</p>
<p>ARTISS</p>
<p>Frozen</p>
<p><span class="Bold">TOPICAL USE
                                ONLY</span></p>
<p><span class="Bold">DO
                                NOT
                            INJECT</span></p>
<p>Contents:</p>
<p>Pre-filled
                            syringe containing:</p>
<p>Sealer Protein Solution (1): 2
                            mL, sterile</p>
<p>Sealer Protein (Human) Vapor Heated,
                            Solvent /Detergent Treated</p>
<p><span class="product-label-link" type="condition" conceptid="4299457" conceptname="Fibrinolysis">Fibrinolysis</span> Inhibitor
                            (Aprotinin, Synthetic), 3000 KIU/mL</p>
<p>Thrombin
                            Solution (2): 2 mL, sterile</p>
<p>Thrombin (Human), 4
                            units/mL Vapor Heated, Solvent /Detergent
                            Treated</p>
<p>Calcium Chloride, 40
                            µmol/mL</p>
<p>Do not use on individuals with a known
                            <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to aprotinin and/or any of the active substances or
                            excipients.</p>
<p>The risks and benefits of this product
                            should be discussed with the patient.</p>
<p>Read full
                            prescribing information before use.</p>
<p>Store at -20°C
                            (-4°F) or colder. Unopened pouches, thawed at room temperature, may be
                            stored for up to 14 days at 15-25°C. </p>
<p>The product
                            must be used within 12 hours after warming to 33-37°C or removal form
                            original pouches. </p>
<p>Do not refrigerate, microwave,
                            or re-freeze.</p>
<p>For single use
                            only</p>
<p>No preservative</p>
<p>Latex
                            free</p>
<p>Rx Only</p>
<p>Contents were
                            sterilized and package under aseptic
                            conditions.</p>
<div class="Figure">
<img alt="ARTISS Frozen 4 mL pouch label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=38a6412e-9557-45ad-a917-da15109657ec&amp;name=906c38fb-0400-4440-8cc8-de27b2836640-10.jpg"><p class="MultiMediaCaption">ARTISS Frozen 4 mL
                                pouch label</p>
</div>
<p>NDC 0944-8503-04</p>
<p>Fibrin
                            Sealant (Human)</p>
<p>ARTISS 4
                            mL</p>
<p>Frozen</p>
<p>Baxter</p>
<p>Contents:</p>
<p><span class="Bold">Pre-filled syringe
                            containing</span>:</p>
<p><span class="Bold">Sealer Protein Solution (1)</span>: 2 mL,
                            sterile</p>
<p>Sealer Protein
                            (Human)</p>
<p><span class="product-label-link" type="condition" conceptid="4299457" conceptname="Fibrinolysis">Fibrinolysis</span> Inhibitor (Aprotinin,
                            Synthetic), 3000 KIU/mL</p>
<p><span class="Bold">Thrombin Solution (2)</span>: 2 mL,
                            sterile</p>
<p>Thrombin (Human), 4
                            units/mL</p>
<p>Calcium Chloride, 40
                            µmol/mL</p>
<p>Read directions for thawing and
                            application before use.</p>
<p><span class="Bold">TOPICAL USE ONLY</span></p>
<p><span class="Bold">DO NOT INJECT</span></p>
<p>Store
                            at -20°C (-4°F) or colder. Unopened pouches, thawed at room temperature,
                            may be stored for up to 14 days at 15-25°C. </p>
<p>Do
                            not refrigerate, microwave, or re-freeze.</p>
<p>Rx
                            Only</p>
<p>Contents were sterilized and package under
                            aseptic conditions.</p>
<p><span class="Bold">Baxter Healthcare
                            Corporation</span></p>
<p>Westlake Village, CA 91362
                            USA</p>
<p>U.S. License No. 140</p>
<p>Rx
                            Only</p>
<div class="Figure">
<img alt="ARTISS 4 mL Syringe label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=38a6412e-9557-45ad-a917-da15109657ec&amp;name=906c38fb-0400-4440-8cc8-de27b2836640-11.jpg"><p class="MultiMediaCaption">ARTISS 4 mL
                                Syringe label</p>
</div>
<p><span class="Bold">Baxter</span></p>
<p><span class="Bold">Fibrin
                                Sealant (Human)</span></p>
<p><span class="Bold">ARTISS</span></p>
<p><span class="Bold">4 mL</span></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ARTISS 		
					</strong><br><span class="contentTableReg">fibrinogen human thrombin human kit</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">PLASMA DERIVATIVE</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0944-4351</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0944-4351-08</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Quantity of Parts</td></tr>
<tr>
<th scope="col" width="5" class="formTitle">Part #</th>
<th scope="col" class="formTitle">Package Quantity</th>
<th scope="col" class="formTitle">Total Product Quantity</th>
</tr>
<tr class="formTableRowAlt">
<td width="5" class="formItem"><strong>Part 1</strong></td>
<td class="formItem">1 VIAL, GLASS </td>
<td class="formItem">2 mL</td>
</tr>
<tr class="formTableRow">
<td width="5" class="formItem"><strong>Part 2</strong></td>
<td class="formItem">1 VIAL, GLASS </td>
<td class="formItem">2 mL</td>
</tr>
<tr class="formTableRowAlt">
<td width="5" class="formItem"><strong>Part 3</strong></td>
<td class="formItem">1 VIAL, GLASS </td>
<td class="formItem">2 mL</td>
</tr>
<tr class="formTableRow">
<td width="5" class="formItem"><strong>Part 4</strong></td>
<td class="formItem">1 VIAL, GLASS </td>
<td class="formItem">2 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 1 of 4</td></tr>
<tr><td class="contentTableTitle">
<strong>SEALER PROTEIN CONCENTRATE HUMAN 		
					</strong><br><span class="contentTableReg">fibrinogen human powder, for solution</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0944-7112</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">TOPICAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>FIBRINOGEN HUMAN</strong> (FIBRINOGEN HUMAN) </td>
<td class="formItem">FIBRINOGEN HUMAN</td>
<td class="formItem">90 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ALBUMIN (HUMAN)</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HISTIDINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>NIACINAMIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYSORBATE 80</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TRISODIUM CITRATE DIHYDRATE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0944-7112-02</td>
<td class="formItem">2 mL in 1 VIAL, GLASS</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">BLA</td>
<td class="formItem">BLA125266</td>
<td class="formItem">03/19/2008</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 2 of 4</td></tr>
<tr><td class="contentTableTitle">
<strong>THROMBIN HUMAN 		
					</strong><br><span class="contentTableReg">thrombin human powder, for solution</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0944-7344</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">TOPICAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>THROMBIN HUMAN</strong> (THROMBIN HUMAN) </td>
<td class="formItem">THROMBIN HUMAN</td>
<td class="formItem">4 [iU]  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ALBUMIN (HUMAN)</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM CHLORIDE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0944-7344-02</td>
<td class="formItem">2 mL in 1 VIAL, GLASS</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">BLA</td>
<td class="formItem">BLA125266</td>
<td class="formItem">03/19/2008</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 3 of 4</td></tr>
<tr><td class="contentTableTitle">
<strong><span class="product-label-link" type="condition" conceptid="4299457" conceptname="Fibrinolysis">FIBRINOLYSIS</span> INHIBITOR SOLUTION 		
					</strong><br><span class="contentTableReg">aprotinin liquid</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0944-7201</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">TOPICAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>APROTININ</strong></td>
<td class="formItem">3000 [iU]  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0944-7201-02</td>
<td class="formItem">2 mL in 1 VIAL, GLASS</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">BLA</td>
<td class="formItem">BLA125266</td>
<td class="formItem">03/19/2008</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 4 of 4</td></tr>
<tr><td class="contentTableTitle">
<strong>CALCIUM CHLORIDE SOLUTION 		
					</strong><br><span class="contentTableReg">calcium chloride liquid</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0944-7401</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">TOPICAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CALCIUM CHLORIDE</strong></td>
<td class="formItem">40 umol  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0944-7401-02</td>
<td class="formItem">2 mL in 1 VIAL, GLASS</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">BLA</td>
<td class="formItem">BLA125266</td>
<td class="formItem">03/19/2008</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">BLA</td>
<td class="formItem">BLA125266</td>
<td class="formItem">03/19/2008</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Baxter Healthcare Corporation
							(039121363)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Baxter Aktiengesellschaft</td>
<td class="formItem"></td>
<td class="formItem">300434670</td>
<td class="formItem">MANUFACTURE</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 8/2011<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>906c38fb-0400-4440-8cc8-de27b2836640</div>
<div>Set id: 38a6412e-9557-45ad-a917-da15109657ec</div>
<div>Version: 5</div>
<div>Effective Time: 20110829</div>
</div>
</div> <div class="DistributorName">Baxter Healthcare Corporation</div></p>
</body></html>
